These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17050788)

  • 21. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH; Clark DJ; O'Gorman M; Willavize SA; Brayman TG; Grover GS; Walsky RL; Obach RS; Faessel HM
    J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.
    Garza D; Murphy M; Tseng LJ; Riordan HJ; Chatterjee A
    Biol Psychiatry; 2011 Jun; 69(11):1075-82. PubMed ID: 21295286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing the dose of varenicline in patients who do not respond to the standard dose.
    Jiménez-Ruiz CA; Barrios M; Peña S; Cicero A; Mayayo M; Cristóbal M; Perera L
    Mayo Clin Proc; 2013 Dec; 88(12):1443-5. PubMed ID: 24290118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Varenicline--a new chance for smokers?].
    Goniewicz ML; Koszowski B; Czogała J; Sobczak A
    Przegl Lek; 2007; 64(10):899-902. PubMed ID: 18409337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study.
    Feng B; Obach RS; Burstein AH; Clark DJ; de Morais SM; Faessel HM
    Clin Pharmacol Ther; 2008 Apr; 83(4):567-76. PubMed ID: 17971819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoking cessation: an overview of treatment options with a focus on varenicline.
    Stack NM
    Pharmacotherapy; 2007 Nov; 27(11):1550-7. PubMed ID: 17963463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Varenicline-associated acute renal failure.
    Bird ML; Vesta KS
    Ann Pharmacother; 2008 Dec; 42(12):1908-11. PubMed ID: 18984856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers.
    Dunbar G; Demazières A; Monreal A; Cisterni C; Metzger D; Kuchibhatla R; Luthringer R
    J Clin Pharmacol; 2006 Jul; 46(7):715-26. PubMed ID: 16809797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longer course of varenicline therapy improves smoking cessation rates.
    Lee JH; Jones PG; Bybee K; O'Keefe JH
    Prev Cardiol; 2008; 11(4):210-4. PubMed ID: 19476573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.
    Obach RS; Reed-Hagen AE; Krueger SS; Obach BJ; O'Connell TN; Zandi KS; Miller S; Coe JW
    Drug Metab Dispos; 2006 Jan; 34(1):121-30. PubMed ID: 16221753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Varenicline: a novel pharmacotherapy for smoking cessation.
    Jiménez-Ruiz C; Berlin I; Hering T
    Drugs; 2009 Jul; 69(10):1319-38. PubMed ID: 19583451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of varenicline on heart rate variability in healthy smokers and nonsmokers.
    Ari H; Celiloğlu N; Ari S; Coşar S; Doganay K; Bozat T
    Auton Neurosci; 2011 Oct; 164(1-2):82-6. PubMed ID: 21664880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of acute varenicline administration on smoking and eating behavior in humans.
    Stoops WW; Vansickel AR; Glaser PE; Rush CR
    Pharmacol Biochem Behav; 2008 Nov; 91(1):165-9. PubMed ID: 18675291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.
    Rigotti NA; Pipe AL; Benowitz NL; Arteaga C; Garza D; Tonstad S
    Circulation; 2010 Jan; 121(2):221-9. PubMed ID: 20048210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
    Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
    J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute hepatic injury associated with varenicline in a patient with underlying liver disease.
    Franck AJ; Sliter LR
    Ann Pharmacother; 2009 Sep; 43(9):1539-43. PubMed ID: 19638471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varenicline: new drug. Smoking cessation: no better than nicotine.
    Prescrire Int; 2006 Dec; 15(86):210-2. PubMed ID: 17165237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.